Shenyang Pharma Univ. PKMYT1 compound A30

Shenyang Pharma Univ. PKMYT1 compound A30: sourced facts only. name: "Among these, compound A30 exhibited outstanding PKMYT1 kinase inhibitory activity (IC50 = 0.003 μM) and strong antiproliferative effects in CCNE1-amplified tumor cells, demonstrating excellent selectivity at both the kinase and cellular levels." [PMID:40845413]; target: "Among these, compound A30 exhibited outstanding PKMYT1 kinase inhibitory activity (IC50 = 0.003 μM) and strong antiproliferative effects in CCNE1-amplified tumor cells, demonstrating excellent selectivity at both the kinase and cellular levels." [PMID:40845413]; developer: "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, PR China." [PMID:40845413]; modality: "In this study, we employed molecular dynamics (MD) simulation-guided strategies to design a novel series of selective and potent PKMYT1 inhibitors." [PMID:40845413]; stage: "Further investigations revealed that compound A30 exerted a highly synergistic effect with gemcitabine in CCNE1-amplified cancer models." [PMID:40845413]